Acquired skeletal muscle disease
MONDO:0016105An instance of skeletal muscle disease that is acquired during the lifetime of the individual.
Also known as: acquired skeletal muscle disease
166 clinical trials for this condition and its sub-types, 0 tagged with Acquired skeletal muscle disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Acquired skeletal muscle disease
-
Acquired idiopathic inflammatory myopathy 67 trials · 159 incl. sub-types
9 sub-types
- Polymyositis 36 trials · 100 incl. sub-types Sub-types →
- Juvenile idiopathic inflammatory myopathy 2 trials · 42 incl. sub-types Sub-types →
- Antisynthetase syndrome 21 trials
- Immune-mediated necrotizing myopathy 17 trials
- Overlap myositis 2 trials
- Eosinophilic fasciitis 1 trial
- Focal myositis 0 trials
- Idiopathic eosinophilic myositis 0 trials
- Inflammatory myopathy with abundant macrophages 0 trials
-
Idiopathic camptocormia 7 trials
-
Acquired rippling muscle disease 0 trials
1 sub-type
-
Idiopathic dropped head syndrome 0 trials
-
Macrophagic myofasciitis 0 trials
Most studied deeper sub-types
-
Can an oral drug calm inflamed muscles in myositis?
Disease control Stopped earlyResearchers are testing an experimental oral drug called enpatoran in adults with dermatomyositis and polymyositis, two rare muscle-weakening diseases. Participants receive enpatoran or a placebo twice daily for up to 24 weeks while continuing their standard care. The trial measu…
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control Stopped earlyThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Lung disease drug tested in rare muscle condition – trial cut short
Disease control Stopped earlyThis study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatme…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis Stopped earlyThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC